摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-环丙基异烟腈 | 1020747-85-6

中文名称
2-环丙基异烟腈
中文别名
——
英文名称
2-cyclopropylisonicotinonitrile
英文别名
2-cyclopropylpyridine-4-carbonitrile
2-环丙基异烟腈化学式
CAS
1020747-85-6
化学式
C9H8N2
mdl
——
分子量
144.176
InChiKey
NKYRSYFRCRGILM-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    252.1±28.0 °C(Predicted)
  • 密度:
    1.16±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1
  • 重原子数:
    11
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.33
  • 拓扑面积:
    36.7
  • 氢给体数:
    0
  • 氢受体数:
    2

安全信息

  • 海关编码:
    2933399090

SDS

SDS:2182a7ffef131063fb3bf99362088713
查看

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    2-环丙基异烟腈 在 magnesium chloride 作用下, 以 乙醇N,N-二甲基甲酰胺 为溶剂, 反应 2.08h, 生成 4-(4-chlorophenyl)-2-(cyclopropylpyridin-4-yl)thiazole
    参考文献:
    名称:
    Diarylthiazole: An Antimycobacterial Scaffold Potentially Targeting PrrB-PrrA Two-Component System
    摘要:
    Diarylthiazole (DAT), a hit from diversity screening, was found to have potent antimycobacterial activity against Mycobacterium tuberculosis (Mtb). In a systematic medicinal chemistry exploration, we demonstrated chemical opportunities to optimize the potency and physicochemical properties. The effort led to more than 10 compounds with submicromolar MICs and desirable physicochemical properties. The potent antimycobacterial activity, in conjunction with low molecular weight, made the series an attractive lead (antibacterial ligand efficiency (ALE)>0.4). The series exhibited excellent bactericidal activity and was active against drug-sensitive and resistant Mtb. Mutational analysis showed that mutations in prrB impart resistance to DAT compounds but not to reference drugs tested. The sensor kinase PrrB belongs to the PrrBA two component system and is potentially the target for DAT. PrrBA is a conserved, essential regulatory mechanism in Mtb and has been shown to have a role in virulence and metabolic adaptation to stress. Hence, DATs provide an opportunity to understand a completely new target system for antimycobacterial drug discovery.
    DOI:
    10.1021/jm500833f
  • 作为产物:
    描述:
    4-氰基吡啶环丙甲酸 在 ammonium persulfate 、 硫酸silver nitrate 作用下, 以 为溶剂, 反应 0.33h, 以50.5%的产率得到2-环丙基异烟腈
    参考文献:
    名称:
    Diarylthiazole: An Antimycobacterial Scaffold Potentially Targeting PrrB-PrrA Two-Component System
    摘要:
    Diarylthiazole (DAT), a hit from diversity screening, was found to have potent antimycobacterial activity against Mycobacterium tuberculosis (Mtb). In a systematic medicinal chemistry exploration, we demonstrated chemical opportunities to optimize the potency and physicochemical properties. The effort led to more than 10 compounds with submicromolar MICs and desirable physicochemical properties. The potent antimycobacterial activity, in conjunction with low molecular weight, made the series an attractive lead (antibacterial ligand efficiency (ALE)>0.4). The series exhibited excellent bactericidal activity and was active against drug-sensitive and resistant Mtb. Mutational analysis showed that mutations in prrB impart resistance to DAT compounds but not to reference drugs tested. The sensor kinase PrrB belongs to the PrrBA two component system and is potentially the target for DAT. PrrBA is a conserved, essential regulatory mechanism in Mtb and has been shown to have a role in virulence and metabolic adaptation to stress. Hence, DATs provide an opportunity to understand a completely new target system for antimycobacterial drug discovery.
    DOI:
    10.1021/jm500833f
点击查看最新优质反应信息

文献信息

  • Synthesis of Sterically Hindered Primary Amines by Concurrent Tandem Photoredox Catalysis
    作者:Michael C. Nicastri、Dan Lehnherr、Yu-hong Lam、Daniel A. DiRocco、Tomislav Rovis
    DOI:10.1021/jacs.9b10871
    日期:2020.1.15
    methodologies exist for amine synthesis, but the direct synthesis of primary amines with a fully substituted α carbon center is an underdeveloped area. We report a method which utilizes photoredox catalysis to couple readily available O-benzoyl oximes with cyanoarenes to synthesize primary amines with fully substituted α-carbons. We also demonstrate that this method enables the synthesis of amines with α-trifluoromethyl
    伯胺是活性药物成分 (API) 及其中间体的重要结构基序,也是用于生物或催化应用的配体库的成员。胺合成有许多化学方法,但直接合成具有完全取代的 α 碳中心的伯胺是一个欠发达的领域。我们报告了一种利用光氧化还原催化将容易获得的 O-苯甲酰基肟与氰基芳烃偶联以合成具有完全取代的 α-碳的伯胺的方法。我们还证明该方法能够合成具有 α-三氟甲基官能团的胺。根据实验和计算结果,
  • [EN] KCNT1 INHIBITORS AND METHODS OF USE<br/>[FR] INHIBITEURS DE KCNT1 ET PROCÉDÉS D'UTILISATION
    申请人:PRAXIS PREC MEDICINES INC
    公开号:WO2020227101A1
    公开(公告)日:2020-11-12
    The present invention is directed to, in part, compounds and compositions useful for preventing and/or treating a neurological disease or disorder, a disease or condition relating to excessive neuronal excitability, and/or a gain-of-function mutation in a gene (e.g., KCNT1). Methods of treating a neurological disease or disorder, a disease or condition relating to excessive neuronal excitability, and/or a gain-of-function mutation in a gene such as KCNT1 are also provided herein.
    本发明部分涉及用于预防和/或治疗神经系统疾病或紊乱、与过度神经元兴奋性有关的疾病或病况,以及基因(例如KCNT1)中的功能增强突变的化合物和组合物。本文还提供了治疗神经系统疾病或紊乱、与过度神经元兴奋性有关的疾病或病况,以及基因如KCNT1中的功能增强突变的方法。
  • Discovery of the First Orally Available, Selective K<sub>Na</sub>1.1 Inhibitor: <i>In Vitro</i> and <i>In Vivo</i> Activity of an Oxadiazole Series
    作者:Andrew M. Griffin、Kristopher M. Kahlig、Robert John Hatch、Zoë A. Hughes、Mark L. Chapman、Brett Antonio、Brian E. Marron、Marion Wittmann、Gabriel Martinez-Botella
    DOI:10.1021/acsmedchemlett.0c00675
    日期:2021.4.8
    (ADNFLE). Effective treatment options for KCNT1-related disease are absent, and novel therapies are urgently required. We describe the development of a novel class of oxadiazole KNa1.1 inhibitors, leading to the discovery of compound 31 that reduced seizures and interictal spikes in a mouse model of KCNT1 GoF.
    基因KCNT1编码钠激活钾通道 K Na 1.1(Slack、Slo2.2)。 KCNT1基因的变异会诱导离子电流的功能获得(GoF)表型,并导致婴儿和儿童出现一系列顽固性神经系统疾病,包括伴有迁移性局灶性癫痫发作的婴儿期癫痫(EIMFS)和常染色体显性遗传性夜间额叶癫痫(ADNFLE)。 KCNT1相关疾病缺乏有效的治疗方案,迫切需要新的疗法。我们描述了新型恶二唑 K Na 1.1 抑制剂的开发,从而发现了化合物31 ,该化合物可减少KCNT1 GoF 小鼠模型的癫痫发作和发作间期尖峰。
  • Electrochemical Synthesis of Hindered Primary and Secondary Amines via Proton-Coupled Electron Transfer
    作者:Dan Lehnherr、Yu-hong Lam、Michael C. Nicastri、Jinchu Liu、Justin A. Newman、Erik L. Regalado、Daniel A. DiRocco、Tomislav Rovis
    DOI:10.1021/jacs.9b10870
    日期:2020.1.8
    Accessing hindered amines, particularly primary amines α to a fully substituted carbon center, is synthetically challenging. We report an electrochemical method to access such hindered amines starting from benchtop-stable iminium salts and cyanoheteroarenes. A wide variety of substituted heterocycles (pyridine, pyrimidine, pyrazine, purine, azaindole) can be utilized in the cross-coupling reaction
    将受阻胺,特别是伯胺 α 连接到完全取代的碳中心,在合成上具有挑战性。我们报告了一种电化学方法,以从台式稳定的亚胺盐和氰基杂芳烃开始获取此类受阻胺。多种取代的杂环(吡啶、嘧啶、吡嗪、嘌呤、氮杂吲哚)可用于交叉偶联反应,包括被卤化物、三氟甲基、酯、酰胺或醚基团、杂环或未保护的杂环取代的杂环酒精或炔烃。基于 DFT 数据以及循环伏安法和 NMR 光谱的机理洞察表明,质子耦合电子转移机制作为 α-氨基自由基和源自氰基杂芳烃的自由基的杂双自由基交叉偶联的一部分是可操作的。
  • Exploiting Transient Radical Cations as Brønsted Acids for Allylic C–H Heteroarylation of Enol Silyl Ethers
    作者:Tsubasa Nakashima、Haruka Fujimori、Kohsuke Ohmatsu、Takashi Ooi
    DOI:10.1002/chem.202101352
    日期:2021.6.25
    Intermediary radical cations, generated through single-electron oxidation of enol silyl ethers by excited Ir-based photocatalysts, can be exploited as Brønsted acids for the activation of heteroarylcyanides. This strategy enables the direct allylic C−H heteroarylation of enol silyl ethers under visible-light irradiation.
    中间自由基阳离子是通过激发的 Ir 基光催化剂通过烯醇甲硅烷基醚的单电子氧化产生的,可用作布朗斯台德酸来活化杂芳基氰化物。该策略使烯醇甲硅烷基醚在可见光照射下直接烯丙基 CH 杂芳基化成为可能。
查看更多

同类化合物

(S)-氨氯地平-d4 (R,S)-可替宁N-氧化物-甲基-d3 (R)-N'-亚硝基尼古丁 (5E)-5-[(2,5-二甲基-1-吡啶-3-基-吡咯-3-基)亚甲基]-2-亚磺酰基-1,3-噻唑烷-4-酮 (5-溴-3-吡啶基)[4-(1-吡咯烷基)-1-哌啶基]甲酮 (5-氨基-6-氰基-7-甲基[1,2]噻唑并[4,5-b]吡啶-3-甲酰胺) (2S)-2-[[[9-丙-2-基-6-[(4-吡啶-2-基苯基)甲基氨基]嘌呤-2-基]氨基]丁-1-醇 (2R,2''R)-(+)-[N,N''-双(2-吡啶基甲基)]-2,2''-联吡咯烷四盐酸盐 黄色素-37 麦斯明-D4 麦司明 麝香吡啶 鲁非罗尼 鲁卡他胺 高氯酸N-甲基甲基吡啶正离子 高氯酸,吡啶 高奎宁酸 马来酸溴苯那敏 马来酸左氨氯地平 顺式-双(异硫氰基)(2,2'-联吡啶基-4,4'-二羧基)(4,4'-二-壬基-2'-联吡啶基)钌(II) 顺式-二氯二(4-氯吡啶)铂 顺式-二(2,2'-联吡啶)二氯铬氯化物 顺式-1-(4-甲氧基苄基)-3-羟基-5-(3-吡啶)-2-吡咯烷酮 顺-双(2,2-二吡啶)二氯化钌(II) 水合物 顺-双(2,2'-二吡啶基)二氯化钌(II)二水合物 顺-二氯二(吡啶)铂(II) 顺-二(2,2'-联吡啶)二氯化钌(II)二水合物 非那吡啶 非洛地平杂质C 非洛地平 非戈替尼 非尼拉朵 非尼拉敏 阿雷地平 阿瑞洛莫 阿培利司N-6 阿伐曲波帕杂质40 间硝苯地平 间-硝苯地平 锇二(2,2'-联吡啶)氯化物 链黑霉素 链黑菌素 银杏酮盐酸盐 铬二烟酸盐 铝三烟酸盐 铜-缩氨基硫脲络合物 铜(2+)乙酸酯吡啶(1:2:1) 铁5-甲氧基-6-甲基-1-氧代-2-吡啶酮 钾4-氨基-3,6-二氯-2-吡啶羧酸酯 钯,二氯双(3-氯吡啶-κN)-,(SP-4-1)-